Xeomics delivers national genomic programs and precision medicine infrastructure for the populations global medicine has overlooked, extending its benefits to everyone.
Modern medicine was built almost entirely on US and European data. Most of humanity was left out of the research that defines their care.
That gap is a scientific and moral failure. Xeomics exists to correct it by turning underrepresented populations from an afterthought into the foundation of better, more equitable medicine for everyone.
of clinical trials now recruiting patients enroll exclusively from outside the United States (ClinicalTrials.gov · archived), yet the data and tools to serve them barely exist. We build them.
Each business is valuable on its own. Together they form a single loop in which data improves care and care generates more data. Explore each.
We partner directly with hospital networks in markets the data industry has overlooked, then de-identify, structure and enrich their records into a research-grade asset, each patient's full episodic journey across records, imaging, labs and genomics.
We design bespoke, disease-relevant cohorts for governments, pharma and research organizations, enriching the data through targeted whole-genome sequencing. Data is made actionable through the XPMS precision medicine and pharmacogenomics reporting suite.
Seraya combines genomics, wearables and AI coaching to deliver personalized care pathways for chronic conditions such as diabetes: a recurring subscription that measurably improves health outcomes while enriching the data.
Nexa links life sciences directly to 2.44B patients and 6.6M clinicians worldwide for trial recruitment, surveys, panels and point-of-care messaging. The network drives engagement and data capture at scale.
We capture each patient's full episodic journey: records, imaging, labs and genomics, de-identified under local law and onboarded into a government-grade secure cloud. Modern AI models can't source this diversity elsewhere, making it one of the few consented, ethnically-diverse training-data assets available to license.
Longitudinal data from the non-US/non-European populations historically excluded from medical research.
Hospital partnerships are long-term and exclusive for 5+ years; data stays in jurisdiction, under partner ownership. A growing, defensible asset.
Patient consent, de-identification and linkage permissions aligned to GDPR and local jurisdictional law.
De-identified, replicated and secured in Syntium Cloud, our proprietary government-grade data platform.
Because data is pre-consented and onboarded into Syntium Cloud, partners skip months of procurement: value delivered in days to weeks, not months.
Cleansed, coded, translated, linked and enriched with genetic and behavioral context: research-ready.
Pharma, CROs, HEOR, AI and academia: scope in seconds, analyze inside a Trusted Research Environment.
Explore the customer path → For data partnersHospitals, health systems, EMR vendors, registries and national programs: data stays in-country, under your ownership.
Become a Syntium partner →Access is provided through partner networks. Availability varies by partner, country and modality.
Modern medicine was built on US and European data. Our footprint is deliberately the opposite: the majority of records are sourced outside the US & Europe. Explore the regions powering the asset.
Regions illustrate sourcing strategy. Representative network countries are named on the Syntium pages; partner and client names are disclosed under briefing, never published.
We don't just sequence; we build national capability that reduces costs and improves health outcomes. Cohort design, a genomic center of excellence, local capacity building, and data governance and security implemented to be retained and sustained by the nation.
We help governments and health systems build genomic programs around the diseases and populations that matter most locally, not just healthy volunteer datasets. This creates more useful data for clinical care, public health, and research.
Xeomics supports end-to-end program execution, from cohort design and sequencing workflows to precision medicine and pharmacogenomic reporting. The result is a practical national capability that can be embedded into routine care.
National programs become more powerful when genomic data is connected to longitudinal health records, outcomes, and population-level disease patterns. This enables earlier risk detection, more personalized treatment, and better public-health planning.
By combining population-scale genomics with clinical context, national programs can support biomarker discovery, drug-target identification, and AI-driven research. Countries retain sovereign control of their primary data while participating in the value created from future discoveries.
A turnkey genomic and pharmacogenomic reporting solution for governments, hospitals, labs, clinics and life-sciences institutions: patient-friendly summaries backed by clinician-grade detail and full scientific bibliography.
Our Tier-1 pharmacogenomic report is among the most comprehensive available: 500+ drugs, 1,060 genes, 2,725 markers, generated from both whole-genome and exome-based sequences.
36 clinical reports span blood & immune, cardiovascular, sensory, endocrine, gastrointestinal, mental health, skin, bone & muscle, nephrological, neuronal, reproductive and respiratory disease groups.
Seraya combines health records, genomic insight, and real-time wearables data, then applies AI-driven coaching to deliver personalized care pathways for chronic conditions.
A genomic profile personalizes each patient's care pathway from the start.
Real-time signals from wearable devices keep care responsive between visits.
Adaptive guidance that responds to the patient's own data, day to day.
A subscription model with strong retention as patients see daily, measurable benefit.
Continuous glucose monitoring plus data-driven care. Early results show reduced insulin dependence under physician supervision and signs of improved glucose regulation.
Insight from records, genetics and wearables combined into one continuous view.
The same integrated, data-driven model applied to neurological conditions.
Nexa is the connective tissue of the platform: a global, on-demand network linking life sciences directly to verified clinicians and patients for care optimization, trials, surveys, advisory boards and messaging.
Clinicians and patients, screened across specialties, geographies and health systems.
Studies fielded fast, with rigorous screening and compliance.
Patient outcomes linked to HCP insight in one place.
Ongoing programs to engage with patients via network of physicians.
Guideline-driven care messages and decision support that lift adherence, close gaps in care, and improve outcomes while lowering cost.
Short, targeted surveys executed rapidly across specialties and geographies.
Faster enrollment for trials and longitudinal engagement programs.
Structured expert engagement, including advisory boards and Delphi panels, plus standing registries embedded directly into clinical workflows.
Insight for consultancies and medical-communications agencies.
2.44B patients and 6.6M clinicians reachable worldwide for targeted, criteria-based engagement.
Size and analyze patient populations across the network.
Recruitment, PRO capture and adherence programs.
Complementary, never a gateway. Data access is always through Syntium. See how →
For the populations medicine overlooked, trust is the product. Consent, sovereign data control, and benefit-sharing are designed in from the first conversation, never bolted on.
Countries retain ownership of their primary data and a stake in the value future discoveries create.
Participating populations share in outcomes and value, turning ethics into a durable, defensible moat.
Consent, de-identification and linkage permissions aligned to GDPR and local jurisdictional law.
De-identified, replicated and secured in Syntium Cloud, our proprietary government-grade platform.
Projected size of the global digital-health market by 2033, up from $347.4B in 2025 (Grand View Research · archived).
Projected CAGR of AI in healthcare through 2030 (Forbes Tech Council · archived).
Of clinical trials now recruiting patients enroll exclusively outside the United States, where diverse data is scarce (ClinicalTrials.gov · archived).
Diverse real-world evidence, market-access and reimbursement studies, and bespoke disease cohorts built from data you can't source elsewhere.
Reach the non-US trial populations most recruiting studies now depend on, and structure trials in a fraction of the usual time.
Consented, ethically-sourced, ethnically-diverse training data, plus synthetic data for adjacent industries.
Company news and perspectives on genomics, precision medicine, AI and global health equity.
Video. Our Chief Innovation Officer joins Bianca Nobilo to trace the thinking machine from Talos to Turing, and to ask what today’s systems are and are not.
Watch →By Dr. George Zarkadakis in Re:solve Global Health. Generative AI is moving medicine toward general medical intelligence; the task is making sure clinicians and patients everywhere benefit.
Read article →Africa holds the greatest human genetic diversity on Earth, yet remains underrepresented in genomics — why national genome projects matter for precision medicine everywhere.
Read article →Now an Organizational Member of GA4GH, a milestone in our mission to advance responsible genomics and global health-data innovation.
Read article →By Dr. George Zarkadakis. Gene therapies have moved from science fiction to clinical reality, yet the cost remains staggering.
Read article →Healthcare, data, AI, cybersecurity, finance and global affairs, built to operate with governments and the world's important institutions.
Former head of AI & Data, Publicis Sapient.
Investment banker; ex-JPMorgan, BofA, UBS. Structured investments, fintech and asset management.
Serial technology entrepreneur; strategy and BD leader across Asia and the Middle East.
Former First Sea Lord and head of the UK Royal Navy; cybersecurity authority.
Former Managing Director, Genomics England; Director at Cancer Research UK; NHS Advisor.
Former VP Global Product Development, Clarivate; founder & CEO of Patient Connect.
Former Global Lead of Secondary Data, OPEN Health; 20 years in real-world data. Syntium →
Data-trust pioneer; ex-Accenture and Willis Towers Watson; PhD in AI for medicine.
Former Group Creative Director & Visualization practice lead, Publicis Sapient; former NIH Panelist.
Technology & cybersecurity leader; ex-Goldman Sachs, Deutsche Bank and AT&T Bell Labs.
Former Delivery Lead for Publicis Groupe flagship AI program.
Whether you're a government, a life-sciences partner, a data or AI team, a provider, or an investor, start the conversation.